Marksans Pharma's Subsidiary, Relonchem, Gets Marketing Authorisation for Metformin Hydrochloride Oral Solution from UK MHRA

Marksans Pharma Ltd's wholly owned subsidiary, Relonchem Ltd, has received Marketing Authorisation for its product Metformin Hydrochloride 500mg/ 5ml Oral Solution from the UK Medicines & Healthcare Products Regulatory Agency. This authorisation marks a significant milestone for Marksans Pharma, which is headquartered in Mumbai, India and engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain Management, Gastroenterological and Anti- allergies. The company is marketing these products globally.